Finance

Beta
Lists
STRO:NASDAQ
Sutro Biopharma Inc
$30.52
+3.28%
(+0.97) 1D
$30.52
-0.00% (-0.00050)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STRO...
Open
$29.67
High
$31.16
Low
$28.75
Mkt. cap
505.73M
Avg. vol.
318.45K
Volume
2.77M
52-wk high
$43.85
52-wk low
$6.74
EPS
-$16.35
Beta
1.54
Shares outstanding
16.57M
No. of employees
133
Open
$29.67
High
$31.16
Low
$28.75
Mkt. cap
505.73M
Avg. vol.
318.45K
Volume
2.77M
52-wk high
$43.85
52-wk low
$6.74
EPS
-$16.35
Beta
1.54
Shares outstanding
16.57M
No. of employees
133
News stories
From sources across the web
Profile
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
About Sutro Biopharma Inc
CEO-
Employees133
Founded2003
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitesutrobio.com
Analyst ratings
Based on 10 analysts giving stock ratings to STRO in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
1
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for STRO in the last 3 months.
Highest
Current $30.52
$60.00 (+96.59%)
Average
$50.50 (+65.47%)
Lowest
$41.00 (+34.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lukas Shumway
Barclays
Buy
Maintained
$56.00
+83.5%
06/23/2026
Supawat Thongthip
Truist Financial
Buy
Initiated
$50.00
+63.8%
06/11/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$54.00
+76.9%
05/30/2026
Unknown Analyst
Barclays
Buy
Initiated
$56.00
+83.5%
05/28/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$50.00
+63.8%
05/26/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$50.00
+63.8%
05/26/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
-
-
05/21/2026
David Nierengarten
Wedbush
Buy
Upgraded
$60.00
+96.6%
05/18/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$43.00
+40.9%
05/15/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
05/14/2026
Salim Syed
Mizuho Securities
Buy
Initiated
$50.00
+63.8%
04/30/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$50.00
+63.8%
04/30/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$41.00
+34.3%
04/23/2026
James Shin
Deutsche Bank
Buy
Reiterated
$55.00
+80.2%
03/25/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Upgraded
$27.00
-11.5%
03/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
63.74M
9.69M
11.65M
14.52M
Cost of goods sold
38.32M
39.85M
36.64M
801.00K
Cost of revenue
38.32M
39.85M
36.64M
801.00K
Research and development expenses
-
-
-
35.75M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.34M
8.74M
8.66M
7.58M
Operating expense
10.34M
8.74M
8.66M
43.34M
Total operating expenses
48.67M
48.59M
45.30M
44.14M
Operating income
15.08M
-38.90M
-33.66M
-29.61M
Other non operating income
-
-
-
-
EBT including unusual items
-11.52M
-56.86M
-46.84M
-38.50M
EBT excluding unusual items
6.90M
-47.30M
-42.45M
-38.46M
Income tax expense
-18.00K
-
-82.00K
-15.00K
Effective tax rate
0.16%
-
0.17%
0.04%
Other operating expenses
-
-
-
-
Net income
-11.50M
-56.86M
-46.76M
-38.48M
Net profit margin
-18.04%
-586.58%
-401.49%
-264.99%
Earnings per share
-1.40
-5.57
-4.88
-2.94
Interest and investment income
2.52M
2.01M
1.53M
1.64M
Interest expense
-10.69M
-10.41M
-10.33M
-10.48M
Net interest expenses
-8.17M
-8.40M
-8.80M
-8.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
16.98M
-37.00M
-32.03M
-28.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of STRO
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer